BOSTON, July 26 /PRNewswire-FirstCall/ -- PAREXEL International Corporation , a leading global bio/pharmaceutical services provider, today announced that Ellen Zane has been elected to its Board of Directors. Ms. Zane is President and Chief Executive Officer of Tufts-New England Medical Center (Tufts-NEMC) and Floating Hospital for Children, located in Boston, Massachusetts. Prior to joining Tufts-NEMC, Ms. Zane held the position of Network President for Partners HealthCare System, also in Boston, where she was responsible for development of a provider network of hospitals and physician groups, which now represents one of the largest physician networks in the United States. Ms. Zane has also served in several other chief executive and senior management positions at New England area hospitals.
"Ellen is a highly accomplished healthcare executive, and we welcome her leadership and expertise on our Board," said Josef von Rickenbach, PAREXEL's Chairman and Chief Executive Officer. "PAREXEL's vision to advance healthcare aligns well with Ellen's background and we look forward to her insight into how our business can better achieve its operational and financial goals."
Ms. Zane is currently a member of the Board of Directors of the Fiduciary Trust Company, the John F. Kennedy Library Foundation, and the Massachusetts Hospital Association, and she also serves on the Board of Overseers at the Tufts University School of Medicine. She is a Trustee of Northeastern University and is a member of the Health Policy and Management Executive Council at the Harvard School of Public Health. Ms. Zane was a former Board member of the biotech company Variagenics, now Nuvelo, and has served as a member of the Board of Governors at the Warren Grant Magnuson Clinical Center at the National Institutes of Health.
Ms. Zane received her B.A. degree from George Washington University and M.A. degree from the Catholic University of America. She holds an honorary Doctorate of Business Administration from Stonehill College and an honorary Doctorate of Humane Letters from Curry College.
Ms. Zane has received many awards and honors recognizing her accomplishments, including the 2006 Progress & Promise Award from the American Liver Foundation. She was recognized as Regional Healthcare Executive of the Year in 1997 by the American College of Healthcare Executives, and received the Distinguished Healthcare Executive Award in 1995 from the Healthcare Management Association of Massachusetts.
Ms. Zane is currently an Assistant Professor in the Department of Medicine, Division of Clinical Care Research at Tufts University School of Medicine.
About PAREXEL
PAREXEL is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions and tracking tools, Interactive Voice Response Systems (IVRS), Clinical Trial Management Systems (CTMS), electronic diary and investigator database solutions. Perceptive also offers advanced medical diagnostics services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. PAREXEL's integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 52 locations throughout 39 countries around the world, and has 5,445 employees.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets" and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward- looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the amendment or interpretation of Financial Accounting Standards Board Statement No. 123 (revised 2004), Share-Based Payment ("Statement 123R"), which could change the Company's current assessment of the effects of the adoption of Statement 123R on the acceleration of equity grants, the assumptions inherent in equity pricing models under Statement 123R and the final results of the closing of the Company's books for future financial periods; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2006 as filed with the SEC on May 9, 2006, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
Contact: Jill Baker Vice President, Investor Relations Tel: 781-434-4118 Email: Jill.Baker@PAREXEL.com
PAREXEL International CorporationCONTACT: Jill Baker, Vice President, Investor Relations, +1-781-434-4118,Jill.Baker@PAREXEL.com
Web site: http://www.parexel.com//
